Takeda scores a win for a rare type of lung cancer, gearing up for a showdown with J&J
Four months after J&J’s infused drug Rybrevant scored the industry’s first win in a rare type of non-small cell lung cancer (NSCLC), Takeda is following up with an oral option for the small but desperate patient population.
The FDA granted an accelerated approval to Takeda’s oral TKI inhibitor Exkivity (mobocertinib) in metastatic NSCLC patients with EGFR exon 20 gene mutations who had previously undergone platinum-based chemotherapy, the company announced on Wednesday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 118,000+ biopharma pros reading Endpoints daily — and it's free.